ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Case Report



Livolin Forte's Modulatory Effect on Haematological Parameters Caused by Sub-chronic Lead Acetate Administration In Wistar Rats

Ezekiel Moses,Mohammed Mamman,Mufta Shittu.




Abstract

ABSTRACT

Aim: This study evaluated the pretreatment and post-treatment effects of Livolin Forte® (LF) on haematological changes caused by sub-chronic lead acetate administration in male Wistar rats.
Methods: Thirty-six male rats weighing were divided into six groups. Group I received distilled water, Group II received propylene glycol, Group III received Livolin Forte®, Group IV received Lead acetate, Group V received LF® followed by lead acetate (pretreatment), and Group VI received lead acetate followed by LF (post-treatment). The regimen was given orally once a day for seven weeks. Blood sample was collected for the evaluation of haematological parameters at the end of the dosing period.
Results: Significantly (P≤0.05) lowered packed cell volume, red blood cell count, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration; of the lead acetate exposed rats, the pretreatment and the post-treatment groups respectively.
Conclusion: LF had no pretreatment and post-treatment effects on sub chronic lead acetate induced alterations in haematological parameters in adult male Wistar rats.

Key words: Livolin forte, lead acetate, toxicity, blood, sub-chronic






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.